Generated by AI
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics and vaccines for neurodegenerative diseases and other misfolded protein disorders. The company works on treatments designed to selectively target toxic protein species linked to conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis, Parkinson’s disease, and multiple system atrophy. Its research platform combines protein biology, physics, and computational methods to identify disease-specific epitopes on misfolded proteins, supporting a pipeline of precision medicine candidates. ProMIS Neurosciences also develops therapies aimed at other central nervous system disorders, reflecting its broader focus on protein misfolding biology in neurological disease. Headquartered in Toronto, Canada, with offices in Cambridge, Massachusetts, ProMIS Neurosciences plays a specialized role in the biotechnology market as a developer of targeted approaches for complex neurological conditions.
Website1920 Yonge Street
Toronto, ON, M4S 3E2
Canada
The latest articles about PMN.
Summary of Nov 16's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Summary of Nov 11's posts. Generated by AI.
Investors talking about PMN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.